Vitamin Shoppe Beats on Both Top and Bottom Lines
Vitamin Shoppe (NYS: VSI) reported earnings on Nov. 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), Vitamin Shoppe beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew significantly.
Margins increased across the board.
Vitamin Shoppe logged revenue of $239.0 million. The 12 analysts polled by S&P Capital IQ foresaw net sales of $234.7 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $208.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.54. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.46 per share. GAAP EPS of $0.54 for Q3 were 35% higher than the prior-year quarter's $0.40 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.5%, 130 basis points better than the prior-year quarter. Operating margin was 10.4%, 200 basis points better than the prior-year quarter. Net margin was 6.8%, 110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $223.3 million. On the bottom line, the average EPS estimate is $0.40.
Next year's average estimate for revenue is $953.8 million. The average EPS estimate is $2.05.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 47 members out of 59 rating the stock outperform, and 12 members rating it underperform. Among 23 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 14 give Vitamin Shoppe a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vitamin Shoppe is outperform, with an average price target of $63.40.
If you're invested in retailers like Vitamin Shoppe, you should check out the concept that is The Motley Fool's top stock for 2012. Its founder wrote the book on big box retailing, and it's growing in increasingly important international markets. Click here for instant access to this free report.
- Add Vitamin Shoppe to My Watchlist.
The article Vitamin Shoppe Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.